TERMINATION AGREEMENTTermination Agreement • May 6th, 2021 • Puma Biotechnology, Inc. • Pharmaceutical preparations • New York
This TERMINATION AGREEMENT (this “Agreement”) is made and entered into effective as of February 24, 2021 (the “Effective Date”), by and between CANbridge BIOMED Limited, a corporation organized and existing under the laws of Hong Kong (“CANbridge”), and PUMA Biotechnology, Inc., a corporation organized and existing under the laws of Delaware, USA (“PUMA”), in the presence of Pierre Fabre Medicament SAS, a company duly organized and existing under the laws of France, having offices and principal place of business at 45 Place Abel Gance, 92100 Boulogne, France (“PFM”). CANbridge and PUMA are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FOURTH AMENDMENT TO amended and restated LOAN AND SECURITY AGREEMENTLoan and Security Agreement • May 6th, 2021 • Puma Biotechnology, Inc. • Pharmaceutical preparations
THIS FOURTH AMENDMENT to Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into as of February 3, 2021, by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time (including Oxford in its capacity as a Lender) (each a “Lender” and collectively, the “Lenders”), and PUMA BIOTECHNOLOGY, INC., a Delaware corporation with offices located at 10880 Wilshire Blvd., Ste. 2150, Los Angeles, CA 90024 (“Borrower”).
Amendment n°3 to License AgreementLicense Agreement • May 6th, 2021 • Puma Biotechnology, Inc. • Pharmaceutical preparations
This amendment n°3 (this “Amendment”) is entered into as of February 24, 2021 (the “Amendment 3 Effective Date”), by and between Puma Biotechnology, Inc., a corporation organized and existing under the laws of the State of Delaware (“Licensor”), and Pierre Fabre Medicament SAS, a corporation organized and existing under the laws of France (“Licensee”) (together with Puma, the “Parties” and each individually a “Party”), and amends the License Agreement, dated as of March 29, 2019, as amended, September 17, 2019 and November 21, 2019, respectively (the “Agreement”), by and between Licensor and Licensee. Capitalized terms used but not defined herein have the respective meanings assigned to them in the Agreement.
